Description

IQVIA Holdings’ Drug Launch Activity Jumps 45% — Is Commercial Growth Reaccelerating?

IQVIA Holdings Inc. reported its second quarter 2026 financial results with revenue, adjusted EBITDA, and adjusted diluted earnings per share surpassing the high end of guidance. The company achieved an 8.7% year-over-year reported revenue growth (8.5% on a constant currency basis), propelled by 6% organic growth, tripling the growth rate from the previous year. Adjusted EBITDA increased by 9.2% year-over-year, while adjusted diluted EPS grew 12.1% to $3.15, driven chiefly by operational execution. The performance was broad-based, with no single notable or atypical contract skewing results, maintaining cancellation rates and pass-through costs within historical norms. IQVIA’s business is organized into two segments: R&D Solutions and Commercial Solutions. R&D Solutions reported 8.8% revenue growth (8.6% on a constant currency basis), driven by a 19% year-over-year increase in net new bookings, including a book-to-bill ratio of 1.22x.